The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
The approval comes following a phase 3 EV-303 trial that showed a 60% reduction in the risk of disease recurrence, progression or death, and a 50% reduction in the risk of death compared to surgery alone. Event-free survival was 74.7% with the combination therapy, versus 39.4% with surgery alone, according to the Nov. 21 press release from Pfizer. Two-year survival was 79.7% versus 63.1%, respectively.
Padcev targets nectin-4, a protein highly expressed in bladder cancer, and is already approved in combination with pembrolizumab for advanced urothelial cancer.
Adverse events of grade 3 or higher occurred in 71.3% of patients in the combination arm and 45.9% in the surgery-alone arm. The safety profile of the combination therapy was consistent with previous reports, according to the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
